Form 4: Candel Therapeutics Director Paul B. Manning Boosts Stake with Over 1 Million Share Acquisition

Paul B. Manning, a Director and 10% owner of Candel Therapeutics, Inc., acquired 1,070,663 shares of common stock at $4.67 per share in a registered direct offering.

Summary

• Paul B. Manning, a Director and 10% owner of Candel Therapeutics, Inc. (CADL), acquired 1,070,663 shares of the company's common stock.
• The acquisition occurred on June 25, 2025, at a price of $4.67 per share.
• This transaction was part of a registered direct offering, as per a Securities Purchase Agreement dated June 23, 2025.
• Following this transaction, Mr. Manning's total beneficial ownership in Candel Therapeutics, Inc. is 5,197,821 shares, held directly and indirectly through The Paul B. Manning Revocable Trust and BKB Growth Investments, LLC.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: The acquisition of a significant number of shares by a director and 10% owner indicates strong insider confidence in the company's prospects, which is generally a positive signal for investors.

Positives

• A Director and 10% owner, Paul B. Manning, significantly increased his stake in Candel Therapeutics, Inc. by acquiring over 1 million shares.
• This insider purchase demonstrates strong confidence in the company's future prospects by a key stakeholder.
• The acquisition was part of a registered direct offering, indicating the company successfully raised capital.

Future Outlook

The document does not provide specific forward-looking statements or guidance beyond the details of the share acquisition.

Management Comments

• Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025.
• The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the 'Trust'). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
• The shares are held directly by BKB Growth Investments, LLC ('BKB'). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
• Includes shares held jointly with spouse.

Industry Context

This insider share acquisition by a director and significant owner in Candel Therapeutics, a biotechnology company, is a common signal of confidence in the company's pipeline or strategic direction within the often volatile biotech sector. Such transactions can be viewed positively by investors, suggesting belief in future clinical trial success or commercialization potential.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The acquisition by a significant insider may instill confidence and potentially lead to positive share price movement. It also indicates a capital raise has occurred, which provides funds for company operations.
• Company: The company successfully raised capital through a registered direct offering, providing funds for its operations.

Key Dates

Recommendation

Keywords

Candel Therapeutics, CADL, Paul B. Manning, Insider Trading, Form 4, Share Acquisition, Director Purchase, Registered Direct Offering, Equity Investment, Biotechnology